Highland Hospital

Summary

Highland Hospital is a medical facility located in Rochester, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Squamous Cell Carcinoma, Cancer and other specialties. Highland Hospital is involved with conducting 132 clinical trials across 173 conditions. There are 3 research doctors associated with this hospital, such as Paul M. Barr, Yuhchyau Chen, and Richard G. Moore.

Top PIs

Clinical Trials running at Highland Hospital

Prostate Cancer

Oropharyngeal Carcinoma

Laryngeal Cancer

Lung Cancer

Throat Cancer

Pancreatic Cancer

Breast Cancer

Cancer

Laryngeal Squamous Cell Carcinoma

Oral Squamous Cell Carcinoma

Shorter vs Usual Radiation Therapy

for Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.

Recruiting

2 awards

Phase 3

10 criteria

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Recruiting

2 awards

Phase 3

30 criteria

Apalutamide + Hormone and Radiation Therapies

for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

Recruiting

2 awards

Phase 3